GRK2: A Fresh Target for Alzheimer’s Therapy Shows Promise in Mice

Scientists identify the enzyme GRK2, and its inactive form, as a new target in Alzheimer's disease. In mouse models and some human brain tissue, inactive GRK2 accumulates with mitochondria, boosting amyloid-beta production and harming mitochondrial function. The compound dubbed Compound 10 prevents GRK2 from clumping, restoring mitochondrial health, reducing amyloid-beta, and slowing dementia progression in mice, marking a potential new therapeutic avenue that still needs validation in humans.